Light Mode
$0.3710 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.3710, $0.0123 below the day’s high of $0.3833
-1.33 (-78.18%) / 6M
Momentum, market sentiment, and recent alerts
RKTO reads poor: the 12-month move is -78.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.